Info all Articles

We are preventing progression of already existing disease," Kandalaft said. "Most of the patients are now on a maintenance vaccine, just to keep the system going. We haven't seen them recur. We are seeing how long they can go. - Lana Kandalaft, PharmD, PhD, MTR

Press releases this week, from the Abramson Cancer Center, and Penn Medicine report media coverage surrounding the ACC's recent collaborative research efforts with the Ovarian Cancer Research Center.  

Lana Kandalaft, PharmD, PhD, MTR, a research assistant professor of Obstetrics and Gynecology and director of clinical development and operations in Penn Medicine's Ovarian Cancer Research Center reported Saturday, during the American Association for Cancer Research's annual meeting, that a new immunotherapy approach that uses patients' own tumor tissue and dendritic cells is helping make headway against a formidable foe -- late-stage ovarian cancer."

The ACC press release highlights the work of the trial's principle investigator Janos Tanyi, MD, PhD, an assistant professor of Obstetrics and Gynecology.

TV stories about the new research also aired on NBC and FOX news affiliates in 106 cities across the nation, including Boston, New Orleans, Philadelphia, and Washington, DC.

• Penn Medicine News Release
• Bloomberg News article
• Philadelphia Inquirer article
• U.S. News and World Report (via HealthDay News)
• MedPage Today
• OB-GYN News article and video
• NBC video